Proof already exists that it works for many patients. But, we need continued philanthropic support to further test the immunotherapy at Roswell Park so that we can improve the treatment of lung cancer and maintain the momentum of this important historic initiative.

Your support gives hope to lung cancer patients, especially those at high risk for recurrence. And, with your help, Roswell Park will be closer to investigating other potential uses of CIMAvax-- not only for advanced lung cancer...

Diabetic foot ulcer is a principal diabetic complication. It has been shown that diabetic patients have decreased growth factor concentrations in their tissues, particularly epidermal growth factor. Growth factor shortage impairs wound healing, which leads to chronic nonhealing wounds and sometimes eventual amputation. Ischemic diabetic foot ulcer is the most difficult to treat and confers the highest amputation risk.
Injecting epidermal growth factor deep into the wound bottom and contours encourages a more effective pharmacodynamic response in terms of granulation tissue growth and wound closure.
Epidermal growth factor injected into the ulcer matrix may also result in association with extracellular matrix proteins, thus enhancing cell proliferation and migration. Heberprot-P is an innovative Cuban product containing recombinant human epidermal growth factor for peri- and intra-lesional infiltration; evidence reveals it accelerates healing of deep and complex ulcers, both ischemic and neuropathic, and reduces diabetes-related amputations